Authors: Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z PMID: 32171076 PMCID: PMC7270627 DOI: 10.1016/S0140-6736(20)30566-3 Abstract Background: Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients [...]
Authors: Rossignol JF PMID: 25108173 PMCID: PMC7113776 DOI: 10.1016/j.antiviral.2014.07.014 Abstract Originally developed and commercialized as an antiprotozoal agent, nitazoxanide was later identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza. A Phase 2b/3 clinical trial recently published in The Lancet Infectious Diseases found that oral administration of nitazoxanide [...]


